

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 May 2018 (03.05.2018)



(10) International Publication Number
WO 2018/081437 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C12Q 1/6886 (2018.01)
A61K 31/337 (2006.01) A61P 35/00 (2006.01)
C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2017/058555

(22) International Filing Date:

26 October 2017 (26.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/413,198 26 October 2016 (26.10.2016) US

(71) Applicant: LEAP THERAPEUTICS, INC. [US/US]; 47
Thorndike Street, Suite B1-1, Cambridge, MA 02141 (US).

(72) Inventors: KAGEY, Michael, H.; 28 Brand Street, Arling-
ton, MA 02474 (US). SIRARD, Cynthia, A.; 47 Thorndike
Street, Suite B1-1, Cambridge, MA 02141 (US).

(74) Agent: ABELLEIRA, Susan, M. et al.; Foley Hoag LLP,
Seaport West, 155 Seaport Blvd., Boston, MA 02210-2600
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: USE OF BETA-CATENIN AS A BIOMARKER FOR TREATING CANCERS USING ANTI-DKK-1 ANTIBODY

(57) Abstract: A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.



WO 2018/081437 A1

- 1 -

USE OF BETA-CATENIN AS A BIOMARKER FOR TREATING CANCERS USING
ANTI-DKK-1 ANTIBODY

RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Application No. 62/413,198, filed on October 26, 2016. The entire teachings of the above application is incorporated herein by reference.

BACKGROUND OF THE INVENTION

[0002] Cancer remains an important public health threat with poor prognosis and limited treatment available for many types. There is a significant unmet need for therapies that can increase efficacy in treating cancers, particularly esophageal cancer, uterine cancer, liver cancer, and cholangiocarcinoma or bile duct cancer. The present application provides such therapies.

SUMMARY OF THE INVENTION

[0003] The present invention relates to a method of treating cancers (*e.g.*, esophageal adenocarcinoma) in a subject in need of treatment.

[0004] Accordingly, in one aspect, the present invention is a method of treating a cancer in a subject in need thereof. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. Alternatively, the cancer can be a stomach cancer. The method comprises administering to the subject a therapeutically effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein (SEQ ID NO:2).

[0005] In another aspect, the present invention is a method of treating a subject suffering from a cancer. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. Alternatively, the cancer can be a stomach cancer. The method com-

prises the steps of obtaining a sample of a neoplastic cell from the subject; determining a sequence of the beta-catenin protein in the sample; and administering to the subject a therapeutically effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof if the sequence of a beta-catenin protein (SEQ ID NO: 2) includes a constitutively activating mutation.

[0006] In yet another aspect, the present invention is a method of treating a cancer in a subject in need thereof. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. Alternatively, the cancer can be a stomach cancer. The method comprises administering to the subject a therapeutically effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject has a constitutively activating mutation of the beta-catenin protein (SEQ ID NO: 2).

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] The foregoing will be apparent from the following more particular description of example embodiments of the invention, as illustrated in the accompanying drawings. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments of the present invention.

[0008] FIG. 1 is a table presenting the analysis of CTNNB1 (beta-catenin) protein mutational data in patients subject to DKN-01 therapy.

[0009] FIG. 2A is a plot indicating the change (in percent of size) in the lesion size in Patient 105-023 suffering from esophageal cancer and put on a combination therapy of Paclitaxel and DKN-01. Patient 105-023 was shown to have a deletion of exons 2 through 4 of the CTNNB1 (beta catenin) gene.

[0010] FIG. 2B is a tomographic image of the target lesion of Patient 105-023 at the inception of the study and at cycle 10.

[0011] FIG. 3A through 3F illustrate the sequence of the human CTNNB1 gene.

[0012] FIG. 4A through 4D collectively represent Table 1 which shows examples of mutations of the beta-catenin protein.

DETAILED DESCRIPTION OF THE INVENTION

[0013] A description of example embodiments of the invention follows.

[0014] Dickkopf-1 (Dkk-1) is a protein that acts as a natural inhibitor of the canonical Wnt/ β -catenin signaling pathway. The Wnt pathway influences a number of biological processes such as cell growth, cell proliferation, stem cell maintenance, cell differentiation, cell polarity, bone development, and adult tissue homeostasis.

[0015] In a canonical Wnt/ β -catenin signaling pathway, extracellular Wnt ligand binds to its cognate receptor “Frizzled,” and further recruits transmembrane lipoproteins LPR5 and LPR6 (low-density lipoprotein receptor-related proteins 5 and 6) co-receptors. Formation of a Wnt/Frizzled/LPR5/6 complex triggers several intracellular signaling cascades, including the one mediated by the β -catenin protein, a gene product of the CTNNB1 gene. In particular, the formation of a Wnt/Frizzled/LPR5/6 complex results in stabilization of cytoplasmic level of beta-catenin due to the inhibition of the beta-catenin phosphorylation. While phosphorylated beta-catenin is degraded in the cytoplasm, unphosphorylated beta-catenin translocates to the nucleus, where it enhances target gene expression of, *e.g.*, cyclin D1, c-myc, c-jun, cyclooxygenase-2, matrix metalloproteinase-7, vascular endothelial growth factor, and survivin, among other growth factors. Absent the signal from the Wnt/Frizzled/LPR5/6 complex, beta-catenin is phosphorylated by intracellular kinases, such as glycogen synthase kinase 3 β (GSK3 β) and casein kinase I (CKI). Transduction of a signal from the Wnt/Frizzled/LPR5/6 complex inhibits this phosphorylation.

[0016] Extracellular Dkk-1 binds to the LPR5/6 co-receptors and prevents Wnt ligand binding. This results in resuming of beta-catenin phosphorylation and its subsequent degradation, thus inhibiting canonical Wnt signaling pathway.

[0017] See URL “<https://www.ncbi.nlm.nih.gov/gene/1499>” for the nucleotide sequence and genomic (chromosomal) coordinates of human CTNNB1. Briefly, genomic (chromosomal) coordinates of CTNNB1 gene are chr3:41,240,942-41,281,939. All coordinates are from build GRCh37/hg19. Nucleotide sequence of CTNNB1 is provided in SEQ ID NO: 1 (includes exons, indicated by capital letters). The gene product of human CNNTB1 gene, referred herein as beta-catenin or beta-catenin protein, is a protein having the sequence provided by SEQ ID NO: 2 (UniProt accession No. P35222). Of particular interest are Exons 2, 3, and 4, corresponding in SEQ ID NO: 2 to amino acid residues 1 through 4 (Exon 2), 5-81 (Exon 3), and 82-165 (Exon 4). The amino acid sequences of the Exons 2 through 4 are provided by SEQ ID Nos: 3, 4, and 5, respectively.

[0018] As used herein, “a constitutively activating mutation of a beta-catenin protein” refers to a mutation of the amino acid sequence of beta-catenin that results in an elevated cellular level of beta-catenin functionally capable of transducing a signal to the cell nucleus, when compared to a wild type protein. Examples of constitutively activating mutations of beta-catenin include mutations that result in its inability to be phosphorylated by GSK3-beta kinase and/or casein kinase I in the absence of the Wnt/Frizzled/LPR5/6 complex. Examples of such mutations include: deletions of Exons 2 through 4, deletion of or within Exon 3, and mutations of the serine and threonine residues that are phosphorylated in the absence of the Wnt/Frizzled/LPR5/6 complex, such as Ser33, Ser37, Thr41, and Ser45 of SEQ ID NO: 2.

[0019] In various embodiments, a mutation of the beta-catenin protein is selected from the mutations listed in Table 1, represented in FIGs. 4A through 4D.

[0020] As those of skill in the art will recognize, “esophageal cancer” as used herein refers to cancer of the esophagus as well as the gastro-esophageal junction. As commonly used in the art, esophageal cancer comprises esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). Generally, ESCC refers to cancer that originates in squamous cells, which cells line the esophagus in approximately upper 2/3 of the organ. EAC refers to cancer that originates in gland cells, which replace an area of squamous cells (*e.g.*, in Barrett’s esophagus), typically in the lower 1/3 of the esophagus. As such, esophageal adenocarcinoma as used herein refers to adenocarcinoma of the esophagus as well as the gastro-esophageal junction.

[0021] “Uterine cancer” is any type of cancer that emerges from the tissue of the uterus. It can refer to several types of cancer, with cervical cancer (arising from the lower portion of the uterus) being the most common type.

[0022] “Liver cancer,” also known as hepatic cancer and primary hepatic cancer, is cancer that starts in the liver. Cancer which has spread from elsewhere to the liver, known as liver metastasis, is more common than that which starts in the liver. Primary liver cancer is globally the sixth most frequent cancer (6%) and the second leading cause of death from cancer (9%).

[0023] “Cholangiocarcinoma” or bile duct cancer is a form of cancer that is composed of mutated epithelial cells (or cells showing characteristics of epithelial differentiation) that originate in the bile ducts which drain bile from the liver into the small intestine. The rates of cholangiocarcinoma have been rising worldwide over the past few decades. Cholangiocarcinoma is considered to be an incurable and rapidly lethal cancer unless both the primary tumor

and any metastases can be fully removed by surgery. No potentially curative treatment exists except surgery, but most people have advanced stage disease at presentation and are inoperable at the time of diagnosis.

[0024] “Stomach cancer” also called *gastric cancer*, is a cancer that starts in the stomach. About 90% to 95% of cancers of the stomach are adenocarcinomas. When the term stomach cancer or gastric cancer is used, it almost always refers to an adenocarcinoma. These cancers develop from the cells that form the innermost lining of the stomach (known as the mucosa).

[0025] The term “effective amount” means an amount of a therapeutic agent, *e.g.* an antibody, that is effective in prophylactically or therapeutically treating the indicated disorder. An “effective amount” may also refer to an amount of a combination of therapeutic agents that is therapeutically or prophylactically sufficient to treat the target disorder. An effective amount will depend on the age, gender, and weight of the patient, the current medical condition of the patient, and the nature of the esophageal cancer being treated. Those of skill in the art will be able to determine appropriate dosages depending on these and other factors.

[0026] It has now been discovered that cancer patients suffering from certain cancers and who have a constitutively activating mutation within the beta-catenin protein (SEQ ID NO: 2) are expected to be more responsive to an anti-Dkk-1 antibody therapy than patients who do not have such a mutation. Accordingly, the present invention relates to a method of treating cancers (*e.g.*, esophageal cancer, uterine cancer, liver cancer, and cholangiocarcinoma) in a subject in need of treatment comprising administering an effective amount of an anti-Dkk-1 antibody, or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of a beta-catenin protein (SEQ ID NO:2).

Dkk-1 Antibody

[0027] Dkk-1 antibodies have been described previously (see, *e.g.*, U.S. Patent Nos. 8,148,498 and 7,446,181, incorporated by reference herein in their entireties). The Dkk-1 antibody or antigen-binding fragment thereof disclosed herein relates to human engineered antibodies that bind to a human Dkk-1 comprising the amino acid sequence set forth in SEQ ID NO: 27, or fragments thereof. The present Dkk-1 antibodies are therapeutically useful Dkk-1 antagonists possessing a number of desirable properties. For example, the Dkk-1 antibodies block Dkk-1 mediated inhibition of alkaline phosphatase, a marker of osteoblast activity, as well as treat various types of cancer (*e.g.*, non-small cell lung cancer).

[0028] A full-length antibody as it exists naturally is an immunoglobulin molecule comprising 2 heavy (H) chains and 2 light (L) chains interconnected by disulfide bonds. The amino terminal portion of each chain includes a variable region of about 100-110 amino acids primarily responsible for antigen recognition via the complementarity determining regions (CDRs) contained therein. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.

[0029] The CDRs are interspersed with regions that are more conserved, termed framework regions ("FR"). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) is composed of 3 CDRs and 4 FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The 3 CDRs of the light chain are referred to as "LCDR1, LCDR2, and LCDR3" and the 3 CDRs of the heavy chain are referred to as "HCDR1, HCDR2, and HCDR3." The CDRs contain most of the residues which form specific interactions with the antigen. The numbering and positioning of CDR amino acid residues within the LCVR and HCVR regions is in accordance with the well-known Kabat numbering convention.

[0030] Light chains are classified as kappa or lambda, and are characterized by a particular constant region as known in the art. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the isotype of an antibody as IgG, IgM, IgA, IgD, or IgE, respectively. IgG antibodies can be further divided into subclasses, e.g., IgG1, IgG2, IgG3, IgG4. Each heavy chain type is characterized by a particular constant region with a sequence well known in the art.

[0031] As used herein, the term "monoclonal antibody" (Mab) refers to an antibody that is derived from a single copy or clone including, for example, any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Mabs of the present invention preferably exist in a homogeneous or substantially homogeneous population. Complete Mabs contain 2 heavy chains and 2 light chains.

[0032] Unless specified otherwise, the term "Dkk-1 antibody" encompasses both a full-length antibody as well as an antigen binding-fragment of the Dkk-1 antibody.

[0033] "Antigen-binding fragments" of such monoclonal antibodies include, for example, Fab fragments, Fab' fragments, F(ab')₂ fragments, and single chain Fv fragments. Monoclonal antibodies and antigen-binding fragments thereof can be produced, for example, by recombinant technologies, phage display technologies, synthetic technologies, e.g., CDR-grafting, or combinations of such technologies, or other technologies known in the art. For example, mice

can be immunized with human DKK-1 or fragments thereof, the resulting antibodies can be recovered and purified, and determination of whether they possess binding and functional properties similar to or the same as the antibody compounds disclosed herein can be assessed by the methods known in the art. Antigen-binding fragments can also be prepared by conventional methods. Methods for producing and purifying antibodies and antigen-binding fragments are well known in the art and can be found, for example, in Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 5-8 and 15, ISBN 0-87969-314-2.

[0034] Monoclonal Dkk-1 antibodies disclosed herein are engineered to comprise framework regions that are substantially human or fully human surrounding CDRs derived from a non-human antibody. "Antigen-binding fragments" of such human engineered antibodies include, for example, Fab fragments, Fab' fragments, F(ab')₂ fragments, and single chain Fv fragments. "Framework region" or "framework sequence" refers to any one of framework regions 1 to 4. Human engineered antibodies and antigen-binding fragments thereof encompassed by the antibodies disclosed herein include molecules wherein any one or more of framework regions 1 to 4 is substantially or fully human, *i.e.*, wherein any of the possible combinations of individual substantially or fully human framework regions 1 to 4, is present. For example, this includes molecules in which framework region 1 and framework region 2, framework region 1 and framework region 3, framework region 1, 2, and 3, *etc.*, are substantially or fully human. Substantially human frameworks are those that have at least about 80% sequence identity to a known human germline framework sequence. Preferably, the substantially human frameworks have at least about 85%, about 90%, about 95%, or about 99% sequence identity to a known human germline framework sequence.

[0035] Human engineered antibodies in addition to those disclosed herein exhibiting similar functional properties can be generated using several different methods. The specific antibody compounds disclosed herein can be used as templates or parent antibody compounds to prepare additional antibody compounds. In one approach, the parent antibody compound CDRs are grafted into a human framework that has a high sequence identity with the parent antibody compound framework. The sequence identity of the new framework will generally be at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identical to the sequence of the corresponding framework in the parent antibody compound. This grafting may result in a reduction in binding affinity compared to that of the

parent antibody. If this is the case, the framework can be back-mutated to the parent framework at certain positions based on specific criteria disclosed by Queen *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:2869. Additional references describing methods useful in humanizing mouse antibodies include U.S. Pat. Nos. 4,816,397; 5,225,539, and 5,693,761; computer programs ABMOD and ENCAD as described in Levitt (1983) *J. Mol. Biol.* 168:595-620; and the method of Winter and co-workers (Jones *et al.* (1986) *Nature* 321:522-525; Riechmann *et al.* (1988) *Nature* 332:323-327; and Verhoeyen *et al.* (1988) *Science* 239:1534-1536). Methods for identifying residues to consider for back-mutation are known in the art (see, *e.g.*, U.S. Patent No. 8,148,498).

[0036] The methods provided herein relate to the use of a Dkk-1 antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2 and HCDR3, wherein LCDR1 has the amino sequence of SEQ ID NO: 6, HCDR1 has the amino sequence of SEQ ID NO: 9, and HCDR2 has the amino sequence of SEQ ID NO: 10.

[0037] In one embodiment, the Dkk-1 antibody comprises a LCDR1 having the amino sequence of SEQ ID NO: 6, LCDR2 having the amino sequence of SEQ ID NO: 7, LCDR3 having the amino sequence of SEQ ID NO: 8, HCDR1 having the amino sequence of SEQ ID NO: 9, HCDR2 having the amino sequence of SEQ ID NO: 10, and HCDR3 having the amino sequence of SEQ ID NO: 11.

[0038] In another embodiment, the Dkk-1 antibody comprises a LCVR having the amino acid sequence of SEQ ID NO: 12 and a HCVR having the amino acid sequence of SEQ ID NO: 13. In a particular embodiment, the LCVR comprises the amino acid sequence of SEQ ID NO: 16 and the HCVR comprises the amino acid sequence of SEQ ID NO: 17.

[0039] In further embodiments, the Dkk-1 antibody comprises a heavy chain (HC) having the amino acid sequence of SEQ ID NO: 22 and a light chain (LC) having the amino acid sequence of SEQ ID NO: 23. The Dkk-1 antibody or antigen binding-fragment thereof comprising the HC and LC amino acid sequence of SEQ ID NO: 22 and SEQ ID NO: 23, respectively, is referred to herein as DKN-01. In particular, DKN-01 has the molecular/empirical formula C₆₃₉₄ H₉₈₁₀ N₁₆₉₈ O₂₀₁₂ S₄₂ and a molecular weight of 144015 Daltons (intact).

[0040] In certain embodiments, the Dkk-1 antibody disclosed herein is an IgG₄ antibody with a neutralizing activity against human Dkk-1 comprising the sequence set forth in SEQ

ID NO: 27, of a fragment thereof. For example, canonical Wnt signaling is important for osteoblast differentiation and activity. Wnt-3a combined with BMP-4 induces pluripotent mouse C2C12 cells to differentiate into osteoblasts with a measurable endpoint of alkaline phosphatase ("AP"), a marker of osteoblast activity. Dkk-1, an inhibitor of canonical Wnt signaling, inhibits the differentiation and production of AP. Neutralizing Dkk-1 antibodies prevent Dkk-1-mediated inhibition of AP. Antibodies which block Dkk-1 inhibitory activity prevent the loss of AP activity (see U.S. Patent No. 8,148,498). In a particular embodiment, the Dkk-1 antibody possessing neutralizing activity is DKN-01, which is an IgG₄ antibody.

[0041] The Dkk-1 antibodies disclosed herein possess high affinity (K_d) to Dkk-1 (*e.g.*, human Dkk-1, SEQ ID NO: 27), as described in U.S. Patent No. 8,148,498. For example, the present Dkk-1 antibodies possess a K_d of between 0.5×10^{-12} M and 3.0×10^{-11} M, at 37 °C.

Modes of Administration

[0042] The Dkk-1 antibody and chemotherapeutic agents for use in the methods or compositions of the invention can be formulated for parenteral, oral, transdermal, sublingual, buccal, rectal, intranasal, intrabronchial or intrapulmonary administration.

[0043] For parenteral administration, the compounds for use in the methods or compositions of the invention can be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus dose and/or infusion (*e.g.*, continuous infusion). Suspensions, solutions or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing and/or dispersing agents can be used.

[0044] For oral administration the compounds can be of the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (*e.g.*, polyvinylpyrrolidone or hydroxypropylmethylcellulose); fillers (*e.g.*, lactose, microcrystalline cellulose or calcium phosphate); lubricants (*e.g.*, magnesium stearate, talc or silica); disintegrates (*e.g.*, sodium starch glycolate); or wetting agents (*e.g.*, sodium lauryl sulphate). If desired, the tablets can be coated using suitable methods. Liquid preparation for oral administration can be in the form of solutions, syrups or suspensions. The liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (*e.g.*, sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters

or ethyl alcohol); and preservatives (*e.g.*, methyl or propyl p-hydroxy benzoates or sorbic acid).

[0045] For buccal administration, the compounds for use in the methods or compositions of the invention can be in the form of tablets or lozenges formulated in a conventional manner.

[0046] For rectal administration, the compounds for use in the methods or compositions of the invention can be in the form of suppositories.

[0047] For sublingual administration, tablets can be formulated in conventional manner.

[0048] For intranasal, intrabronchial or intrapulmonary administration, conventional formulations can be employed.

[0049] Further, the compounds for use in the methods or compositions of the invention can be formulated in a sustained release preparation. For example, the compounds can be formulated with a suitable polymer or hydrophobic material which provides sustained and/or controlled release properties to the active agent compound. As such, the compounds for use in the method of the invention can be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation. Various methods of formulating controlled release drug preparations are known in the art.

[0050] Administration of a compound, or pharmaceutically acceptable salt thereof, or a composition comprising one or more compound (or pharmaceutical salt thereof) of the invention useful to practice the methods described herein, can be continuous, hourly, four times daily, three time daily, twice daily, once daily, once every other day, twice weekly, once weekly, once every two weeks, once a month, or once every two months, or longer, or some other intermittent dosing regimen.

[0051] Examples of administration of a compound, or a composition comprising one or more compound (or pharmaceutical salt thereof) of the invention include peripheral administration. Examples of peripheral administration include oral, subcutaneous, intraperitoneal, intramuscular, intravenous, rectal, transdermal, or intranasal forms of administration.

[0052] As used herein, peripheral administration includes all forms of administration of a compound or a composition comprising a compound of the instant invention which excludes intracranial administration. Examples of peripheral administration include, but are not limited to, oral, parenteral (*e.g.*, intramuscular, intraperitoneal, intravenous or subcutaneous injection, extended release, slow release implant, depot and the like), nasal, vaginal, rectal, sublingual or topical routes of administration, including transdermal patch applications and the like.

Combination Therapy

[0053] The Dkk-1 antibody disclosed herein can be used for treating esophageal cancer in combination with a second amount of a chemotherapeutic agent (sometime referred to herein as a “second agent”). Such combination administration can be by means of a single dosage form which includes a Dkk-1 antibody and the second agent, such single dosage form including a tablet, capsule, spray, inhalation powder, injectable liquid or the like. Combination administration can comprise a further second agent (*e.g.*, chemotherapeutic agent) in addition to the single dosage form. Alternatively, combination administration can be by means of administration of two different dosage forms, with one dosage form containing a Dkk-1 antibody, and the other dosage form including a second amount of a chemotherapeutic agent. In this instance, the dosage forms may be the same or different. Without wishing to limit combination therapies, the following exemplifies certain combination therapies which may be employed. It is understood that additional chemotherapeutic agents beyond the required second amount of a chemotherapeutic agent can be employed in the method described herein.

[0054] The second amount of the chemotherapeutic agent (sometimes referred to herein as the second agent) can be administered before, simultaneously with, or after the administration of a Dkk-1 antibody. Accordingly, a Dkk-1 antibody and a second agent can be administered together in a single formulation or can be administered in separate formulations, *e.g.*, either simultaneously or sequentially, or both. For example, if a Dkk-1 antibody and a second agent are administered sequentially in separate compositions, the Dkk-1 antibody can be administered before or after the chemotherapeutic agent. The duration of time between the administration of a Dkk-1 antibody and the second amount of the chemotherapeutic agent will depend on the nature of the chemotherapeutic agent. In certain embodiments, the Dkk-1 antibody can precede or follow a chemotherapeutic agent immediately, or after some duration of time deemed to be appropriate by a skilled practitioner.

[0055] In addition, the Dkk-1 antibody and the second amount of the chemotherapeutic agent may or may not be administered on similar dosing schedules. For example, the Dkk-1 antibody and the chemotherapeutic agent may have different half-lives and/or act on different time-scales such that the Dkk-1 antibody is administered with greater frequency than the chemotherapeutic agent or vice-versa. For example, the Dkk-1 antibody and the chemotherapeutic agent can be administered together (*e.g.*, in a single dosage or sequentially) on one

day, followed by administration of only the chemotherapeutic agent (or a different chemotherapeutic) a set number of days later. The number of days in between administration of therapeutic agents can be appropriately determined according to the safety and pharmacodynamics of each drug. Either the Dkk-1 antibody or the chemotherapeutic agent can be administered acutely or chronically.

[0056] As used herein, an “effective amount” refers to an amount of a therapeutic agent or a combination of therapeutic agents that is therapeutically or prophylactically sufficient to treat the target disorder. An effective amount will depend on the age, gender, and weight of the patient, the current medical condition of the patient, and the nature of the esophageal cancer being treated. Those of skill in the art will be able to determine appropriate dosages depending on these and other factors.

[0057] Suitable doses per administration for a Dkk-1 antibody include doses of about or greater than about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1100 mg, about 1125 mg, about 1150 mg, about 1175 mg, about 1200 mg, about 1225 mg, about 1250 mg, about 1275 mg, about 1300 mg, about 1325 mg, about 1350 mg, about 1375 mg, about 1400 mg, about 1425 mg, about 1450 mg, about 1475 mg, about 1500 mg, about 1525 mg, about 1550 mg, about 1575 mg, about 1600 mg, about 1625 mg, about 1650 mg, about 1675 mg, about 1700 mg, about 1725 mg, about 1750 mg, about 1775 mg, about 1800 mg, about 1825 mg, about 1850 mg, about 1875 mg, about 1900 mg, about 1925 mg, about 1950 mg, about 1975 mg, about 2000 mg, about 2025 mg, about 2050 mg, about 2075 mg, about 2100 mg, about 2125 mg, about 2150 mg, about 2175 mg, about 2200 mg, about 2225 mg, about 2250 mg, about 2275 mg, about 2300 mg, about 2325 mg, about 2350 mg, about 2375 mg, about 2400 mg, about 2425 mg, about 2450 mg, about 2475 mg, about 2500 mg, about 2525 mg, about 2550 mg, about 2575 mg, about 2600 mg, or about 3,000 mg. Each suitable dose can be administered over a period time deemed appropriate by a skilled practitioner. For example, each suitable dose can be administered over a period of about 30 minutes and up to about 1 hour, about 2 hours, about 3, hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, or about 8 hours. In a particular embodiment, a suitable dose for Dkk-1 antibody can be about 150 mg administered over a period of about 30 minutes and

up to about 2 hours. Another suitable dose for the Dkk-1 antibody can be about 300 mg administered over a period of about 30 minutes and up to about 2 hours.

[0058] Suitable doses per administration for a second amount of chemotherapeutic agent can be determined based on the recommended dosing found on the label. When paclitaxel in the second amount of the chemotherapeutic agent used doses of about or greater than about 8 mg/m², 10 mg/m², about 15 mg/m², about 20 mg/m², about 25 mg/m², about 30 mg/m², about 35 mg/m², about 40 mg/m², about 45 mg/m², about 50 mg/m², about 55 mg/m², about 60 mg/m², about 65 mg/m², about 70 mg/m², about 75 mg/m², about 80 mg/m², about 85 mg/m², about 90 mg/m², about 95 mg/m², about 100 mg/m², about 105 mg/m², about 110 mg/m², about 120 mg/m², about 130 mg/m², about 140 mg/m², about 150 mg/m², about 160 mg/m², about 170 mg/m², about 180 mg/m², about 190 mg/m², about 200 mg/m², about 225 mg/m², about 250 mg/m², about 275 mg/m², about 300 mg/m², about 600 mg/m² or about 800 mg/m². For example, a suitable dose per administration of paclitaxel is about 80 mg/m² over a period of about 1 hour.

[0059] An effective amount can be achieved in the methods or compositions of the invention by coadministering a first amount of a Dkk-1 antibody (or a pharmaceutically acceptable salt, hydrate or solvate thereof) and a second amount of at least one chemotherapeutic agent. In one embodiment, the Dkk-1 antibody and the chemotherapeutic agent are each administered in a respective effective amount (*e.g.*, each in an amount which would be therapeutically effective if administered alone). In another embodiment, the Dkk-1 antibody and the chemotherapeutic agent are each administered in an amount which alone does not provide a therapeutic effect (a sub-therapeutic dose). In yet another embodiment, the Dkk-1 antibody can be administered in an effective amount, while the chemotherapeutic agent is administered in a sub-therapeutic dose. In still another embodiment, the Dkk-1 antibody can be administered in a sub-therapeutic dose, while the chemotherapeutic agent is administered in an effective amount.

[0060] As used herein, the term “subject” refers to a mammal, preferably a human, but can also mean an animal in need of veterinary treatment, *e.g.*, companion animals (*e.g.*, dogs, cats, and the like), farm animals (*e.g.*, cows, sheep, pigs, horses, and the like) and laboratory animals (*e.g.*, rats, mice, guinea pigs, and the like).

[0061] As used herein “treating” includes achieving, partially or substantially, delaying, inhibiting or preventing the progression of clinical indications related to the cancer being treated. For example, “treating” includes reduction in tumor growth, or prevention of further

growth, as detected by standard imaging methods known in the art, including, for example, computed tomography (CT) scan, magnetic resonance imaging (MRI), chest x-ray, and CT/positron emission tomography (CT/PET) scans, and evaluated according to guidelines and methods known in the art. For example, responses to treatment can be evaluated through the Response Evaluation Criteria in Solid Tumors (RECIST) (Revised RECIST Guideline version 1.1; see Eisenhauer *et al.*, *Eur. J. Cancer* 45(2):228-47, 2009). Thus, in some embodiments, "treating" refers to a Complete Response (CR), which is defined according to the RECIST guideline as the disappearance of all target lesions, or a Partial Response (PR), which is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Other means for evaluating tumor response to treatment include evaluation of tumor markers and evaluation of performance status (*e.g.*, assessment of creatinine clearance; see Cockcroft and Gault, *Nephron*. 16:31-41, 1976).

Pharmaceutical Composition

[0062] The Dkk-1 antibody and chemotherapeutic agents disclosed herein can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the antibody, or one or more chemotherapeutic agents, or both, and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.

[0063] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with

acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0064] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL(TM) (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0065] Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, a Dkk-1 antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0066] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form

of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0067] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0068] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid- derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.

[0069] For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0070] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0071] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to

methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

[0072] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

[0073] While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

EXEMPLIFICATION

Example 1 – Detection of Constitutively Activating Mutations of CTNNB1 Gene

[0074] Biopsy samples can be obtained from a patient for determination of the sequence of the beta-catenin gene. Gene sequencing is well within the purview of a person of ordinary skill in the art, and can be accomplished using commercially available products, such as the Archer® VariantPlex Solid Tumor kit available from ArcherDX, Inc. of Boulder, CO, and next generation sequencing platforms such as one available from Illumina, Inc. of San Diego CA (Worldwide Headquarters). Comparison can be done to publically available genetic sequence of the gene, *e.g.* at the NCBI database.

Example 2 – Detection of Constitutively Activating Mutations of beta-Catenin Protein

[0075] Phosphorylation status of beta-catenin can be determined by western blot analysis with antibodies that recognize the phosphorylated form of beta-catenin. Stabilization and activation of beta-catenin can be determined by western blot demonstrating an increase in cellular protein levels and by immunofluorescence demonstrating nuclear localization of beta-catenin. Measuring the expression of downstream beta-catenin target genes or an exogenous beta-catenin reporter gene construct can be utilized to determine the activation status of beta-catenin.

Example 3 – CTNNB1 Mutational Data in Patients Subject to DKN-01 TherapyClinical Study of the Paclitaxel /DKN-01 Combination Therapy

[0076] Patients were selected for a clinical investigation of the combination DKN-01/Paclitaxel® therapy designed as a phase 1 non-randomized, dose-escalating, open label, multicenter study.

[0077] Patients with histologically confirmed recurrent or metastatic esophageal or gastro-esophageal junction adenocarcinoma were selected. Each patient reported on in Table 1 was placed on a 28-day treatment cycle: 300 mg of DKN-01 antibody on days 1 and 15; 80 mg/m² of Paclitaxel® on days 1, 8, 15, and 22.

[0078] DKN-01 was administered intravenously (IV) over a minimum of 30 minutes and up to a maximum of 2 hours without interruption. Paclitaxel® was administered IV over 1 hour on days 1, 8, 15 and 22 of each cycle according to standard clinical practice. Standard of care premedication for paclitaxel was given prior to administration. Sequence of administration: pre-medication for paclitaxel, DKN-01, paclitaxel. DKN-01 was administered first followed by paclitaxel on Days 1 and 15 when both drugs were delivered.

[0079] Biopsy samples, collected prior to commencement of the study, were subject to gene expression analysis.

[0080] Radiological tumor assessment was performed. At a minimum, a computerized tomography (CT) scan of the chest, abdomen and pelvis had been conducted for tumor assessment with documentation of one or more metastatic tumors measurable on radiographic imaging as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Whenever feasible, the preferred imaging modality throughout the study was CT/PET scans. Baseline radiographic tumor assessments were conducted within 28 days prior to day 1 of cycle 1 and subsequent tumor assessments were performed after every even numbered cycle.

[0081] The following response criteria were used:

[0082] Complete Response (CR): Disappearance of all lesions. Any pathological lymph nodes had reduction in short axis to <10 mm. Tumor marker results were normalized.

[0083] Partial Response (PR): At least a 30% decrease in the sum of diameter of lesions, taking as reference the baseline sum diameters.

[0084] Progressive Disease (PD): At least a 20% increase in the sum of the diameters of lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum demonstrated an absolute

increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

[0085] Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Result Analysis

[0086] Analysis of beta-catenin mutations was performed on patients subjected to the combination therapy of Paclitaxel® and DKN-01 according to the methods described above. The results are presented in FIG. 1. As can be seen, the beta-catenin mutations resulting from deletion of Exons 2-4, S45F and T41I are found in patients exhibiting a partial response or at least stable disease.

[0087] This data demonstrates that an activating mutation of beta-catenin is a biomarker predictor of a therapeutic response to an anti-Dkk-1 antibody administration.

Example 4 – Case Study of Patient 105-023: β -Catenin Activating Mutations is a Biomarker for DKN-01 Sensitivity in Esophageal Cancer Therapy

[0088] As shown in FIG. 1, Patient 105-023, suffering from a GEJ adenocarcinoma malignancy, exhibited the highest reduction in tumor volume. Clinical data pertaining to Patient 105-023 was further analyzed.

[0089] Patient 105-023 experienced a tumor regression of 73% over the course of fourteen 28-day treatment cycles. The results are illustrated in FIG. 2A and FIG. 2B. FIG. 2A shows a plot of tumor volume in Patient 105-023 as a function of the number of cycles of treatment (cycles are denoted by start dates). Patient 105-023 received 300 mg of DKN-01 on Days 1 and 15 and 80 mg/m² of paclitaxel weekly during a 28-Day Cycle for the first 10 cycles. During Cycle 10 paclitaxel was discontinued; however the response continued to deepen. FIG. 2B is a computerized tomography image demonstrating a reduction in the size of the primary lesion in Patient 105-023 from baseline to Cycle 10. Arrow denotes the primary lesion.

[0090] As can be seen from the data, Patient 105-023 discontinued paclitaxel in Cycle 10 and has continued to have a deepening response to DKN-01 monotherapy. Genetic analysis of a biopsy sample from this patient's tumor (performed using the methods described in Example 1 by employing a FoundationOne® Panel, commercially available from Foundation

Medicine, Inc., Cambridge, MA) indicated the presence of a β -catenin exon 2-4 deletion that results in constitutive activation.

[0091] This data further supports the finding that an activating mutation of beta-catenin is a biomarker predictor of a therapeutic response to an anti-Dkk-1 antibody administration.

SEQUENCES

The genomic DNA sequence of CTNNB1 – SEQ ID NO: 1

[0092] SEQ ID NO: 1, shown in FIGs. 3A through 3F, represents the sequence of human CTNNB1 gene having the chromosomal coordinates chr3:41,240,942-41,281,939. All coordinates are from build GRCh37/hg19. 5'UTR and 3'UTR exons are not included. Capital letters are the exons, lower case letters are introns. Exons 2, 3, and 4 are underlined and superscripted.

Amino Acid Sequence of beta-Catenin Protein – SEQ ID NO: 2

[0093] SEQ ID NO: 2, below, is the amino acid sequence of human beta-catenin, a 781 amino acid protein UniProt Database ID – P35222 (<http://www.uniprot.org/uniprot/P35222>). Exons 2, 3, and 4 are underlined and superscripted.

<u>2</u>	<u>4</u>	<u>3</u>	10	20	30	40	50
<u>MATQ</u>	<u>ADLMEL</u>	<u>DMAMEPDRKA</u>	<u>AVSHWQQQSY</u>	<u>LDSGIHSGAT</u>	<u>TTAPSLSGKG</u>		
	60	70	80	<u>4</u>	90	100	
<u>NPEEEDVDTS</u>	<u>QVLYEWEQGF</u>	<u>SQSFTQEQVA</u>	<u>DIDGOYAMTR</u>	<u>AQRVRAAMFP</u>			
110	120	130	140	150			
<u>ETLDEGMOIP</u>	<u>STOFDAAHPT</u>	<u>NVORLAEPSQ</u>	<u>MLKHAVVNL</u>	<u>NYODDAELAT</u>			
160	170	180	190	200			
<u>RAIPELTKLL</u>	<u>NDEDOVVVVK</u>	<u>AAVMVHQLSK</u>	<u>KEASRHAIMR</u>	<u>SPQMVSIVR</u>			
210	220	230	240	250			
<u>TMQNTNDVET</u>	<u>ARCTAGTLHN</u>	<u>LSHHREGLLA</u>	<u>IFKSGGIPAL</u>	<u>VKMLGSPVDS</u>			
260	270	280	290	300			
<u>VLFYAITTLH</u>	<u>NLLLHQEGAK</u>	<u>MAVRLAGGLQ</u>	<u>KMVALLNKTN</u>	<u>VKFLAITTDC</u>			
310	320	330	340	350			
<u>LQILAYGNQE</u>	<u>SKLIILASGG</u>	<u>PQALVNIMRT</u>	<u>YTYEKLLWTT</u>	<u>SRVLKVLVSV</u>			
360	370	380	390	400			
<u>SSNKPAIVEA</u>	<u>GGMQALGLHL</u>	<u>TDPSQRLVQN</u>	<u>CLWTLRNLSD</u>	<u>AATKQEGMEG</u>			
410	420	430	440	450			
<u>LLGTLVQLLG</u>	<u>SDDINVVTCA</u>	<u>AGILSNLTCN</u>	<u>NYKNKMMVCQ</u>	<u>VGGIEALVRT</u>			
460	470	480	490	500			
<u>VLRAGDREDI</u>	<u>TEPAICALRH</u>	<u>LTSRHQEAEM</u>	<u>AQNAVRLHYG</u>	<u>LPVVVKLLHP</u>			
510	520	530	540	550			
<u>PSHWPLIKAT</u>	<u>VGLIRNLALC</u>	<u>PANHAPLREQ</u>	<u>GAIPLRVQLL</u>	<u>VRAHQDTQRR</u>			
560	570	580	590	600			
<u>TSMGGTQQQF</u>	<u>VEGVRMEEIV</u>	<u>EGCTGALHIL</u>	<u>ARDVHNRIVI</u>	<u>RGLNTIPLFV</u>			
610	620	630	640	650			
<u>QLLYSPIENI</u>	<u>QRVAAGVLCE</u>	<u>LAQDKEAAEA</u>	<u>IEAEGATAPL</u>	<u>TELLHSRNEG</u>			
660	670	680	690	700			
<u>VATYAAAVLF</u>	<u>RMSEDKPDY</u>	<u>KKRLSVELTS</u>	<u>SLFRTEPMAW</u>	<u>NETADLGLDI</u>			
710	720	730	740	750			
<u>GAQGEPLGYR</u>	<u>QDDPSYRSFH</u>	<u>SGGYGQDALG</u>	<u>MDPMEHEMG</u>	<u>GHHPGADYPV</u>			

760 770 780
 DGLPDLGHAQ DLMDGLPPGD SNQLAWFDTD L

Exons of beta-Catenin Protein

[0094] The amino acid number range does not correspond exactly to the exons as marked in SEQ ID NO: 1 because of the splicing of the transcript. For example the first base “G” of the codon for amino acid #5 is in exon 2 and second and third bases “CT” are in Exon 3.

[0095] Highlighted residues of Exon 3 (in bold and underlined) indicate GSK3B and CK1 α phosphorylation sites that stabilize beta-catenin when they are mutated or deleted): S33, S37, T41, S45. (See de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. (1998). Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 95: 8847-8851; and Xu W, & Kimelman D (2007). Mechanistic insights from structural studies of beta-catenin and its binding partners. J Cell Sci 120: 3337-3344.)

Exon 1 (Non-Coding)

Exon 2 – SEQ ID NO: 3 (amino acids 1-4 of SEQ ID NO: 2)
 MATQ (SEQ ID NO: 3)

Exon 3 – SEQ ID NO: 4 (amino acids 5-81 of SEQ ID NO: 2)
 ADLMELDMAMEPDRKAAVSHWQQQSYLD**SGIHS**
 GAT**TTAP****SL**SGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVAD (SEQ ID NO: 4)

Exon 4 – SEQ ID NO: 5 (amino acids 82-165 of SEQ ID NO: 2)
 IDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAV-
 VNLINYQDDAELATRAIPELTKLLNDEDQ (SEQ ID NO: 5)

[0096] LCDR1
 His Ala Ser Asp Ser Ile Ser Asn Ser Leu His (SEQ ID NO: 6)

[0097] LCDR2
 Tyr Xaa Arg Gln Ser Xaa Gln (SEQ ID NO: 7)
 wherein **Xaa** at position 2 is Gly or Ala; and **Xaa** at position 6 is Ile or Glu

[0098] LCDR3

Gln Gln Ser Xaa Ser Trp Pro Leu His (SEQ ID NO: 8)

wherein **Xaa** at position 4 is Glu or Ala**[0099]** HCDR1

Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser (SEQ ID NO: 9)

[00100] HCDR2

Thr Ile Ser Gly Gly Gly Phe Gly Thr Tyr Tyr Pro Asp Ser Val Lys (SEQ ID NO: 10)

[00101] HCDR3

Pro Gly Tyr Xaa Asn Tyr Tyr Phe Asp Ile (SEQ ID NO: 11)

wherein **Xaa** at position 4 is His or Asn**[00102]** LCVR

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
Cys His Ala Ser Asp Ser Ile Ser Asn Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu Ile Tyr Tyr Xaa Arg Gln Ser Xaa Gln Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Ser Xaa Ser Trp Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys (SEQ ID
NO: 12)

wherein **Xaa** at position 51 is Gly or Ala; **Xaa** at position 55 is Ile or Glu and **Xaa** at position
92 is Glu or Ala.

[00103] HCVR

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Phe Gly Thr Tyr Tyr Pro Asp Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gly Tyr Xaa Asn Tyr Tyr Phe Asp
Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser (SEQ ID NO: 13)

wherein **Xaa** at position 102 is His or Asn

[00104] LCVR

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys His Ala Ser Asp Ser Ile Ser Asn Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Tyr Gly Arg Gln Ser Ile Gln Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Glu Ser Trp Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys (SEQ ID NO: 14)

[00105] HCVR

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Phe Gly Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gly Tyr His Asn Tyr Tyr Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser (SEQ ID NO: 15)

[00106] LCVR

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys His Ala Ser Asp Ser Ile Ser Asn Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Tyr Ala Arg Gln Ser Ile Gln Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Glu Ser Trp Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys (SEQ ID NO: 16)

[00107] HCVR

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Phe Gly Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gly Tyr Asn Asn Tyr Tyr Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser (SEQ ID NO: 17)

[00108] LCVR

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys His Ala Ser Asp Ser Ile Ser Asn Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro

Arg Leu Leu Ile Tyr Tyr Gly Arg Gln Ser Ile Gln Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Ser Ala Ser Trp Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys (SEQ ID NO:
18)

[00109] LCVR

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
Cys His Ala Ser Asp Ser Ile Ser Asn Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu Ile Tyr Tyr Ala Arg Gln Ser Glu Gln Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Ser Ala Ser Trp Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys (SEQ ID NO:
19)

[00110] HC

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Phe Gly Thr Tyr Tyr Pro Asp Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gly Tyr His Asn Tyr Tyr Phe Asp Ile
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val

Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly (SEQ ID NO: 20)

[00111] LC

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
Cys His Ala Ser Asp Ser Ile Ser Asn Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu Ile Tyr Tyr Gly Arg Gln Ser Ile Gln Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Ser Glu Ser Trp Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys (SEQ ID NO: 21)

[00112] HC

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Phe Gly Thr Tyr Tyr Pro Asp Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gly Tyr Asn Asn Tyr Tyr Phe Asp
Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg
Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu
Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly (SEQ ID NO: 22)

[00113] LC

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
Cys His Ala Ser Asp Ser Ile Ser Asn Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu Ile Tyr Tyr Ala Arg Gln Ser Ile Gln Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Ser Glu Ser Trp Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys (SEQ ID NO: 23)

[00114] HC

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Phe Gly Thr Tyr Tyr Pro Asp Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gly Tyr His Asn Tyr Tyr Phe Asp Ile
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val
Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly (SEQ ID NO: 24)

[00115] LC

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
Cys His Ala Ser Asp Ser Ile Ser Asn Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu Ile Tyr Tyr Gly Arg Gln Ser Ile Gln Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Ser Ala Ser Trp Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys (SEQ ID NO: 25)

[00116] LC

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
Cys His Ala Ser Asp Ser Ile Ser Asn Ser Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu Ile Tyr Tyr Ala Arg Gln Ser Glu Gln Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Ser Ala Ser Trp Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys (SEQ ID NO: 26)

[00117] Human Dkk-1 Amino Acid Sequence

Thr Leu Asn Ser Val Leu Asn Ser Asn Ala Ile Lys Asn Leu Pro Pro Pro Leu Gly Gly Ala Ala
Gly His Pro Gly Ser Ala Val Ser Ala Ala Pro Gly Ile Leu Tyr Pro Gly Gly Asn Lys Tyr Gln
Thr Ile Asp Asn Tyr Gln Pro Tyr Pro Cys Ala Glu Asp Glu Glu Cys Gly Thr Asp Glu Tyr
Cys Ala Ser Pro Thr Arg Gly Gly Asp Ala Gly Val Gln Ile Cys Leu Ala Cys Arg Lys Arg

Arg Lys Arg Cys Met Arg His Ala Met Cys Cys Pro Gly Asn Tyr Cys Lys Asn Gly Ile Cys
Val Ser Ser Asp Gln Asn His Phe Arg Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn
Asp His Ser Thr Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser Lys Met Tyr His Thr Lys
Gly Gln Glu Gly Ser Val Cys Leu Arg Ser Ser Asp Cys Ala Ser Gly Leu Cys Cys Ala Arg
His Phe Trp Ser Lys Ile Cys Lys Pro Val Leu Lys Glu Gly Gln Val Cys Thr Lys His Arg Arg
Lys Gly Ser His Gly Leu Glu Ile Phe Gln Arg Cys Tyr Cys Gly Glu Gly Leu Ser Cys Arg Ile
Gln Lys Asp His His Gln Ala Ser Asn Ser Ser Arg Leu His Thr Cys Gln Arg His (SEQ ID
NO: 27)

CLAIMS

1. A method of treating a cancer in a subject in need thereof, the method comprising:
administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof,
wherein the subject is determined to have a constitutively activating mutation of beta-catenin protein (SEQ ID NO:2), and
wherein the cancer is an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma.
2. A method of treating a subject suffering from a cancer, comprising the steps of:
obtaining a sample of a cancer cell from the subject;
determining a sequence of a beta-catenin protein in the sample; and
administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof if the sequence of a beta-catenin protein (SEQ ID NO: 2) includes a constitutively activating mutation,
wherein the cancer is an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma.
3. A method of treating a cancer in a subject in need thereof, the method comprising:
administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof,
wherein the subject has a constitutively activating mutation of a beta-catenin protein (SEQ ID NO: 2), and
wherein the cancer is an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma.
4. The method of any one of Claims 1 to 3, further including administering an effective amount of a chemotherapeutic agent.

5. The method of Claim 4, wherein the chemotherapeutic agent is a taxane, paclitaxel, docetaxel, carbazitaxel, gemcitabine, carboplatin, cisplatin, oxaliplatin, fluorouracil, capecitabine, or tegafor, or any functional analog thereof.
6. The method of any one of Claims 1-5, wherein the anti-Dkk-1 antibody, or antigen binding-fragment thereof, comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2 and HCDR3, wherein LCDR1 has the amino sequence of SEQ ID NO: 6, LCDR2 has the amino sequence of SEQ ID NO: 7, LCDR3 has the amino sequence of SEQ ID NO: 8, HCDR1 has the amino sequence of SEQ ID NO: 9, HCDR2 has the amino sequence of SEQ ID NO: 10, and an HCDR3 has the amino sequence of SEQ ID NO: 11.
7. The method of Claim 6, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 12 and the HCVR comprises the amino acid sequence of SEQ ID NO: 13.
8. The method of Claim 6 or 7, wherein the LCVR and HCVR comprise amino acid sequences selected from the group consisting of: (i) a LCVR comprising the amino acid sequence of SEQ ID NO: 14 and a HCVR comprising the amino acid sequence of SEQ ID NO: 15; (ii) a LCVR comprising the amino acid sequence of SEQ ID NO: 16 and a HCVR comprising the amino acid sequence of SEQ ID NO: 17; (iii) a LCVR comprising the amino acid sequence of SEQ ID NO: 18 and a HCVR comprising the amino acid sequence of SEQ ID NO: 15; (iv) a LCVR comprising the amino acid sequence of SEQ ID NO: 19 and a HCVR comprising the amino acid sequence of SEQ ID NO: 15.
9. The method of Claim 8, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 16 and the HCVR comprises the amino acid sequence of SEQ ID NO: 17.

10. The method of Claim 9, wherein the anti-Dkk-1 antibody comprises a heavy chain and a light chain amino acid sequence selected from the group consisting of a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 24 and light chain comprising the amino acid sequence of SEQ ID NO: 21, b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 22 and a light chain comprising the amino acid sequence of SEQ ID NO: 23, c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 24 and a light chain comprising the amino acid sequence of SEQ ID NO: 25, and d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 24 and a light chain comprising the amino acid sequence of SEQ ID NO: 26.
11. The method of Claim 10, wherein the anti-Dkk-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 22 and a light chain comprising the amino acid sequence of SEQ ID NO: 23.
12. The method of any one of Claims 1-11, wherein the subject is a human.
13. The method of any one of Claim 1 to 3, wherein the mutation includes a deletion of exon 3 (SEQ ID NO: 4).
14. The method of Claim 13, wherein the mutation includes a deletion of Exons 2, 3, and 4 (SEQ ID NOs. 3, 4, and 5).
15. The method of any one of Claim 1 to 3, wherein the mutation includes a deletion within exon 3 (SEQ ID NO: 4).
16. The method of any one of Claim 1 to 3, wherein the mutation is a deletion of any subsequence within the amino acid sequence of the protein of SEQ ID NO: 2, wherein said subsequence includes at least one residue selected from Ser33, Ser37, Thr41, and Ser45.
17. The method of any one of Claim 1 to 3, wherein the mutation is a mutation of any one of the amino acid residues selected from Ser33, Ser37, Thr41, and Ser45 of the protein of SEQ ID NO: 2.

18. The method of any one of Claims 1 to 3, wherein the mutation is any one of the mutations of amino acid residues of in the protein of SEQ ID NO:2 listed in Table 1.
19. A method of treating a cancer in a subject in need thereof, the method comprising:
 - administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof,
 - wherein the subject is determined to have a constitutively activating mutation of beta-catenin protein (SEQ ID NO:2), and
 - wherein the cancer is a stomach cancer.
20. The method of Claim 19, further including administering an effective amount of a chemotherapeutic agent.
21. The method of Claim 20, wherein the chemotherapeutic agent is a taxane, paclitaxel, docetaxel, carbazitaxel, gemcitabine, carboplatin, cisplatin, oxaliplatin, fluorouracil, capecitabine, or tegafur, or any functional analog thereof.
22. The method of any one of Claims 19-21, wherein the anti-Dkk-1 antibody, or antigen binding-fragment thereof, comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2 and HCDR3, wherein LCDR1 has the amino sequence of SEQ ID NO: 6, LCDR2 has the amino sequence of SEQ ID NO: 7, LCDR3 has the amino sequence of SEQ ID NO: 8, HCDR1 has the amino sequence of SEQ ID NO: 9, HCDR2 has the amino sequence of SEQ ID NO: 10, and an HCDR3 has the amino sequence of SEQ ID NO: 11.
23. The method of Claim 22, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 12 and the HCVR comprises the amino acid sequence of SEQ ID NO: 13.

24. The method of Claim 22 or Claim 23, wherein the LCVR and HCVR comprise amino acid sequences selected from the group consisting of: (i) a LCVR comprising the amino acid sequence of SEQ ID NO: 14 and a HCVR comprising the amino acid sequence of SEQ ID NO: 15; (ii) a LCVR comprising the amino acid sequence of SEQ ID NO: 16 and a HCVR comprising the amino acid sequence of SEQ ID NO: 17; (iii) a LCVR comprising the amino acid sequence of SEQ ID NO: 18 and a HCVR comprising the amino acid sequence of SEQ ID NO: 15; (iv) a LCVR comprising the amino acid sequence of SEQ ID NO: 19 and a HCVR comprising the amino acid sequence of SEQ ID NO: 15.
25. The method of Claim 24, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 16 and the HCVR comprises the amino acid sequence of SEQ ID NO: 17.
26. The method of Claim 25, wherein the anti-Dkk-1 antibody comprises a heavy chain and a light chain amino acid sequence selected from the group consisting of a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 24 and light chain comprising the amino acid sequence of SEQ ID NO: 21, b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 22 and a light chain comprising the amino acid sequence of SEQ ID NO: 23, c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 24 and a light chain comprising the amino acid sequence of SEQ ID NO: 25, and d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 24 and a light chain comprising the amino acid sequence of SEQ ID NO: 26.
27. The method of Claim 26, wherein the anti-Dkk-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 22 and a light chain comprising the amino acid sequence of SEQ ID NO: 23.
28. The method of any one of Claims 19-27, wherein the subject is a human.
29. The method of Claim 19, wherein the mutation includes a deletion of exon 3 (SEQ ID NO: 4).

30. The method of Claim 29, wherein the mutation includes a deletion of Exons 2, 3, and 4 (SEQ ID NOs. 3, 4, and 5).
31. The method of Claim 19, wherein the mutation includes a deletion within exon 3 (SEQ ID NO: 4).
32. The method of Claim 19, wherein the mutation is a deletion of any subsequence within the amino acid sequence of the protein of SEQ ID NO: 2, wherein said subsequence includes at least one residue selected from Ser33, Ser37, Thr41, and Ser45.
33. The method of Claim 19, wherein the mutation is a mutation of any one of the amino acid residues selected from Ser33, Ser37, Thr41, and Ser45 of the protein of SEQ ID NO: 2.
34. The method of Claim 19, wherein the mutation is any one of the mutations of amino acid residues of in the protein of SEQ ID NO:2 listed in Table 1.

Patient ID	Response ¹	Cycles on Treatment ¹	CTNNB1 Mutation	Predicted Effect	Allelic Frequency	Gene Panel
105-023	PR (-73%)	16+ cycles (on going)	Exon 2-4 deletion	Stabilizing	Unknown	Foundation One
104-004	PR (-67%)	13+ cycles (on going)	Not detected	NA	NA	Archer VariantPlex Solid Tumor
108-003	PR (-40%)	10 cycles (off treatment)	C-term truncation: Q27Ter	Unknown	6%	Archer VariantPlex Solid Tumor
109-008	PR (-35%)	3+ cycles (on going)	S45F	Stabilizing	2%	Archer VariantPlex Solid Tumor
109-003	SD (-7%)	9+ cycles (on going)	135N T41I	Most likely stabilizing Stabilizing	3% 4%	Archer VariantPlex Solid Tumor
104-014	SD (-6%)	4+ cycles (on going)	Not detected	NA	NA	Solid Tumor Hotspot NGS
109-001	SD (-2%)	3 cycles (off treatment)	Not detected	NA	NA	Archer VariantPlex Solid Tumor
104-016	PD (13%)	2 cycles (off treatment)	Not detected	NA	NA	Guardant 360
104-017	PD (8%)	2 cycles (off treatment)	Not detected	NA	NA	Foundation One
104-020	PD (69%)	2 cycles (off treatment)	Not detected	NA	NA	Archer VariantPlex Solid Tumor
104-018	PD (90%)	2 cycles (off treatment)	D6N	Most likely no effect	11%	Archer VariantPlex Solid Tumor
104-023	PD (260%)	2 cycles (off treatment)	Not detected	NA	NA	Archer VariantPlex Solid Tumor

¹ Response as of 8/3/16, best response. Cycles are 28 day periods -- treatment delays may prolong or adjust these durations.

Legend: Partial response (PR), Stable disease (SD), Progressive disease (PD).

²For the Archer VariantPlex Solid Tumor Gene Panel, the Archer Analysis (version 4.1.0.5) default parameters were used to identify CTNNB1 mutations

FIG. 1




FIG. 2B

FIG. 2A

**CTNNB1 genomic DNA sequence (includes introns)
(SEQ ID NO: 1)**

Exon 2

ATGGCTACTCAAGggtttgtgtcattaatatcttttagttactgaattggggc 50
tctgcttcgttgccattaaagccagtctggctgagatccccctgctttcct
ctctccctgcttacttgtcaggctaccttttgcctccatcttctgctcact
cctcctaattggcttgggtgaaatagcaaaccaagccaccagcaggaatctag
tctggatgactgcttctggagcctggatgcagtaccattcttccactgat
tcagtgagtaactgttaggtgggtccctaagggattaggtatcttcatcac
tgagetaaacctggctatcattctgcttttcttggctgtcttccagatctt
gactttatttctaaaaatatttcaatgggtcatatcacagattctttttt
tttaaataaagtacaacttccaatctactaatgctaataactgtttcgta 400

Exon 3

ttttagctgattttgattggagttggacatggccatgggaaccagacagaaa
AGCGGCTGTTAGTCACTGGCAGCAACAGTCTTACCTGGACTCTGGAATCC 500
ATTCTGGTGGCCACTACCACAGCTCCTTCTCTGAGTGGTAAAGGCAATCCT
GAGGAAGAGGATGTGGATACCTCCCAAGTCTGTATGAGTGGGAACAGGG
ATTTTCTCAGTCTTTCACCTCAAGAACAAGTAGCTGgtaagagtattatt
ttcattgccttactgaaagtacagaatgcagttttgagaactaaaaagtta
gtgtataatagtttaaataaaatgttgtgggtgaagaaaagagagtaatag
caatgtcacttttaccatttaggatagcaataacttaggtaaatgctgaa

Exon 4

ctgtggatagtgagtggtgaattaaccttttccagatattgattggacagt 850
ATGCAATGACTCGAGCTCAGAGGGTACGAGCTGCTATGTTCCCTGAGACA
TTAGATGAGGGCATGCAGATCCCATCTACACAGTTTGATGCTGCTCATCC
CACTAATGTCCAGCSTTTGGCTGAACCATCACAGATGCTGAAACATGCAG 1000
TTGTAACCTTGACTAATCAAGATGATGCAGAACTTGCCACACGTGCA
ATCCCTGAACTGACAAAACCTGCTTAAATGAACGAGGACCAGgtaagcaatga
catagctagcttttttagtctgctttgaaagtaaatgctcaaggggagtagt
ttcagaatgcttaccataccagtaacttgaactaacgatggtttctga
attcctgtattacagGTGGTGGTAAATAAGGCTGCAGTTATGGTCCATCA
GCTTTCTAAAAGGAAGCTTCCAGACACGCTATCATGCGTTCTCTCAGA
TGGTGTCTGTATTGTACGTACCATGCAGATAACAATGATGTAGAAACA
GCTCGTTGTACCGCTGGGACCTTGCATAACCTTTCCCATCATCGTGAGGG
CTTACTGGCCATCTTTAAGTCTGGAGGCATTCCTGCCCTGGTGAAAATGC
TTGGgtaagaaaacatgtcagaatgcttgaagctaaaaagtagaagagta 1500
tactcaaatattctgatgaggctttttcttcttcccagTTCACCAGT
GGATTCTGTGTTGTTTATGCCATTACAACTCTCCACAACCTTTTATTAC
ATCAAGAAGGAGCTAAAATGGCAGTGCCTTFACTGGTGGGCTGCAGAAA
ATGGTTGCCCTTGCTCAACAAAACAAATGTTAAATTTCTTGGCTATTACGAC
AGACTGCCCTTCAAATTTTAGCTTATGGCAACCAAGAAAGCAAGgtaagag
aattattctttatgtggttttcatggagcattggacacctccagtgatcat
gtcattccatgcagtgcttccataaccttttggcaccagggaccagttctg
tggaaaacagtttttccatgaatgggttgggggaatggtttctggatgac
accattccacctcagataatcaggcattagattctcatagggagcgtgca
gcctagatccctcgcatgtgcagtccacactaggggtttctactcctatga 2000
gactctcatgggtgcagttgatctgacaggaggttagagctcaagccaggt
atgctcgtcacctgccacttacctcctgctgtgagcccagttcatttc
tgttcttttaaatttttagtcttccatagtaaaagcactatgcgaagtag
tagggataggttaggcaagcttctcttcaaccttttggctcttaggtggga
tgtagatggtgggaataataaacctaataatttaatttggtagtgggaaga 2250

FIG. 3A

```

agtggggctatgaggggcacataacacaaagttgaaactgactctttttgag 2200
ggttcaaggagacctcttgggaggaagtgatagttgagttcagtggtcaag
gatgagaagggatcactagggtgaagggttaggtgagaaaacaacatctt
gaaacgaaaggaaggagatgggaaagtttgggaatttaagaaatactaata
gtaaggaggaagaaaggttgagggtgaggctattgagatagacttagcag 2500
atctcatagggctttgtagagcatgfttaaaagcacaatgggaaatttca
gcagaagcctgaaatgatgaaatttggttttttagaaaattggggcagtggt
gaaaggggaagatatacagggaaatgaaaggacaagcatgaatgatcatttt
atggtatctggttttaagggtggatataataggaaaattaaagggccaaa
tgatgaggagtttaagtgccagttctggttcaaaattttcagtgaatcagtt
ttgatataactttcatcttagggcattactcttgcctaccaacatagttt
ctaaattttttcttttgggtgtgatcactgtgggaagaaggaaattgggc
ccaaactgatcattgtttggaggactgggatgtctgaatttgagtggaa
tgctttaaaaggacaagttggatagggcccagtatgggggtctgagtga 3000
tggggtccaggaatacatttaggtccaatggcaagctggctgaaattctt
gtataataaaaataggttggtaatatggctcttctcagacatgtgatcaag
attccttgactaacaagatataatataatctttctagCTCATCATACT
GGCTAGTGGTGGACCCCAAGCTTTAGTAAATATAATGAGGACCTATACTT
ACGAAAAACTACTGTGGACCAAGCACAAGCAGAGTGTGAAGGTGCTATCTGTC
TGCTCTAGTAAATAAGCCGGCTATTGTAGAAGCTGGtaagtatatgtatct
attctgagttctgtgtatagcatctgcagttctaatagattacttttct
taggaaaagggtggtagaactttaactactgaaaataaatggctcctattca
gtttgcagccaagatttacatcagagttacctgtcatctggattgtagct
aaaatfttaaggctagtttaggttagagttcttattatccatcaaaaatga 3500
tggcataatggttttgcttaataaaaattggtttgtaatttcagttttgagta
aacctaagatttgctaacagagctgtgaatttataggagaaaagacaaat
tctaataatagttacagttttatgtaaagtgattgctttattagtagatgct
catgagcagtttttggttttgttttaacttttaggttccgggtaatgtgca
ggcttggttatataaggtaaattgcatgtcacaggggtttcgtgtgcagatt
attttgtcaaccagggcagtaagttatgtaccaaataggtagtttttctcag
tctttacctcccacccgtaagtagggcccagtgctgttggttcccttctt
tgtgccogtgbtactcagtgtttacctcccacttaataagtgagaacatg
tggatatttgggtttctattcctatggttagtttgcttaggataatggcctc
cagctccatccatgttgctgaggaagacatcttggatattttttatgggt 4000
gcttagtattccatagtatatgtaccacattttctttatctagtctac
cattgatgggcatttagggttaattccatatactttgctattgtgaataatg
ctgcagtgaaacatagcatgcatgtgtctttatggtaaaaagatttcttt
ttctttgggcatataacctaaataataggattgctggattgaatggtaattc
tgtcaggttttttgagaaatcaccaaaattgctttccacaatggctgaact
aatftactttcccaccagcagtgatataagcattctctttctcagcaacc
tcaccagcatctgtcattttttgactttttattagtagccattctaaactg
gtgtgagacgggtatctcatgtgggttttgatttgcatttctctaagatc
agtgalgtcgagcttttctcoatatgtttcttggccacttgtatgtcttc
ttttgaaaagtgctgttcatgtcctttgcccactttttaatgggggtgt 4500
tctttttgcttggtaatttaagtttattgtaaaactctggatatttagacc
tttgtcagatgcatagtttgccagtaactttctcccagtcagtaactttct
cccattctgtagggttgtctgtttactctgttgatttcttttggctgcccag
aagctcttttaactgtcccattttgtcagtttttggtttttggttgaaacttc
tcttggcatctctgtcatgaaatctttgcccaggtcttatgtccagaatgg
tatttccataggttatcttgcagagttttacagtttttaagttttatattt
aagtcttttaaccattctgagttgatttttgtacatcatgtaaggatggg
gtgcagtttcaatcttggatgtggctagccagttatcccagcaccattta 4750

```

FIG. 3B

```

ttgaatagggagtcccttccccattgcttggttttggcttacttggtaggt 4800
gtgoggcctaacttctgggcttctcttctggtccattgggtctctggtgc
tggttgtataccagtaaccatgctgtgattgtaacottgtattaacagtat
agcttgaagtgggtaaagtgatccctccagttttggtctcttttgcttag
gattgccttggctattcaggctctcttttgggtccatatagaatttttaa 5000
tagttttttttaaattatgtaagaatgccattggtagtttggtaggaat
agcattgaatctgtgaattgcttggggctgtatggccattttaacaatat
tgattcttctgcccataagaatgtaatttctcatttgggtggtcctc
tctgatttcttggagcagtgcttcttggtaattctcattgtagagatctt
cacctccctgggttagttgtattcctaggtattttattcttttgggtt
tggtaaaatgggattgcatctctgatttggcttgcagcttggatggtgtg
gtgtctagaaaatgcttctgactttgtacattgatttttatatccgaaa
cttggctgaagtttatggatcaaggagcttttgggcagagattatgggg
tttctaggtatagaatcatattggttgcacaacagacttctatttggat
gcattttcttctcttggctgatgatgagcagtgcttggccctgatattc 5500
tgtattctcagtgaaatagatgtcgtctaagtatgagaaacaatttttct
tattctgagtatctttaaagaaggcaacttatatgtgggtactttgtatatt
gtgtatgttggcaattggggaaaaagaatagatggttgtactagggcctc
ttgggtctctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt
ttacttttagctaccaagcatttttctctcttccagtaaccacctaac
aacatttactcagaatttcaaagcaagcttcaaatcagtatgaaagaag
gaaaaatataaaggcattttaaaggaaagaatgttgggaataaagtatag
ggctggcaacacttactttctcacttatgagagtaattttacttggga
atltatgagagagaaagacattatgattgctccaggtaactactggcaga
ggaaccatagctcttggggatagacaaaatgtggctgagttcatatagaatg 6000
aggggatgggatgtaaatctgtcagctgttccagcagtaacctgtaatg
taggctaaaaatcacagattttgagatttatttaatacagaatccctggagt
gttaatttttatatacaagatctcatagtgttttatbtgaagtgcagggga
ggctctgtagatagctggacatgtatgggactggaagcttaggaatcttta
agttcttccaggttattcttatgttcatttggtttattctgaaaaatagcat
ctaagtattttaaagaatggaataggccatagbtatacattgggttaaca
caacagatagggctccctgcttaattcttagtcttgtgaagggtgacaaa
aatacttaaaaatagtgatcctaaattagaatgagtggttatgggagaaa
tgacagcaaatagtgatgagaattaatggggaggggaatgtctagatga
gagggaaaaggctctcttggaaaaggatgttaagtgggactgcaggatg 6500
agagggaaaccgtctctgtctatatagagaagtgaggggttaaacgttttcc
aggtagagaaaaggaaaccatgtgctatgtcttagaaccagggatattcc
agtcttttggcttccctgggccaatgggaagaagaataattgtcttggg
ctacacaccaaatacactaatgatagctgatgagctaaaaacaaaaaaaaa
ttgcaaaaagaatctcataatggtttaaagaaagtttacgaatttgggtggg
ctacattcagagctgtcctaggccatgtggcccatgggctgcaggttggg
caagcttgccttagaaggaaagagatgggtcagggcaggtggctcaogcc
tgtaattccagcacttgggaggctgaggtgggctggatcatgaggtcagg
agatcgagaccagcctggctaacacagtgaaaaccccatctctactaaaaa
tcaaaaaagttagccgggctggtggcagggcctgtagtcccagctact 7000
tgggaggctgaggcaggagaatggtgtgaacccgggaggcggagcttgca
gtgagctgagatagcggcactgcaactcagcctgggocgacagagtgagac
tctatctcaaaaaaaaaaaaaagggaagagatttgggagatccaggtgc
tgaagagaaggctctgcataaacagaacttagtaatgaggtggatggcctg
gtatgaggttgggttaggttaagcagagccataaacatgcaggactttcta
ggttcctataagatagttactactcatggagtttattcatgctttattcc
agcttggagccatagatacagaatacttgggtcagtttgggaaggctagg 7350

```

FIG. 3C

tgggatccaaabttctaaacgggttccctcaggggttataactaaagtaatttcta 7400
 ttatcttaaaaggatgctgagacactttcgatgggttgtttatcaatagca
 aagcatcacagtggtgtgtttaaataattaataatagcattgtatagatt 7500
 aacagtttgaatgaccaaaagctagaagaccagactactgagatggtaca
 ggcttttaggaatgaaatagtttgcttttagaactcaatagcaaagggca
 gatgtctgagatgcoctgaaagaatcatagaatgtaataatataggagcta
 agggagcaaccaaaaacgggtttgtggaggggacaacattggtaccatgaa
 gataaatggaaacctcagaaggcacoccttaatttttgaaacataataat
 aagaagctgacttaaagtgacttaaaaggctcagtaggttagctggaaatgt
 atgatactagaatgcaagagagggcaggctagagatttggaaagtttccctc
 ttagtataataggggtaagggcagcaggggaaggggaggttagaggtgccaca
 gagtcatctgtatgggactttttttttaccctagaactgctgaatcaga
 atgtgtgtgttttaaagtctctgtaggccattctgatggacatctgggg 8000
 taaaaatccattctcttagagttaatagttatgtaaaagggagggaaatgaag
 tcttaaagaggggaaagaaggtagtcatttcacaaaatactgagcatcctg
 atcatcagttctacgcagatcattctattagtagctggagctactatgaa
 aaaggaacccaacagaggtgatctttgtcttgtagggaaagtggagtaac
 ttacactatgagggagaagtgcaggggtaccataagaattacagcagatag
 acctcatctgaggaaataaaaacagacccgaaagatgaggagacaaggaa
 agtatactcttactgcattcagaagtgatttaagttgaagatggatgagc
 gaagttaatctactatgtgggcatgggcttccatttataactccttggcc
 agagttaatgtccccatttaagggctcctaaaggatggaagattgtaaac
 cttggaacacatgttttgttagtcaagtgaaattgtataaagtccctgacagt 8500
 aagtgttttcatgcoctctttctggattgttcttaccacaggaatttacc
 tagcttctttagtcttttagtcaagatgtcaccttcacagtgaggtagcct
 aattatctatttfaaaatcgcagccccactccattatttttctccatagcc
 ctttaatatcatctgacatactgtatgggttttagtttattgtatattttt
 ctgcctcttccaaactagatcataaattctgagggtaggaacttctgaata
 ttttggttcactgggtctatctgcagctcagaacaggacctggtagtgaat
 aaatatttttgaatgattgaatggatgaaaagaaatgagtaataagaat
 attacctaagggggacagtgagataaacaaggctttttcggcttaggaa
 aggaacagtagctatttgagagtttgtcactagtgaggtgaaactggcaaa
 gtgaaggaaactgagcaacattctagaaaatgagaggaaatcaaatactt 9000
 aggtgaaaggaagttaaactctggaaatacagaaggacacctcctaaggct
 agaacagatatttaggattgataggcactctagctaatgactagggcct
 tataatcctttttaaattttctagGTGGAATGCAAGCTTTAGGACTTCACCT
 GACAGATCCAAGTCAACGTCCTTGTTCAGAACTGTCTTTGGACTCTCAGGA
 ATCTFTTCAGATGCTGCAACTAAACAGGtaaatctctgagtaaactgggtgcc
 atgggaatagagtcgaagatgagtatgtgcttgtactgaccatctgttttt
 atctccatagGAAGGCATGGAAGGTCTCCTTGGGACTCTTGTTCAGCTTC
 TGGGTTTTCAGATGATATAAATGTGGTCACTTGTGCAGCTGGAATTCCTTCT
 AACCTCACTTCGAATAAATTATAAGAACAAGATGATGGTCTGCCAAGTGGG
 TGGTATAGAGGCTCTTGTGCGTACTGTCTCTCGGGCTGCTGACAGGGAAG 9500
 ACATCACTGAGCCTGCCATCTGTGCTCTTCGTTCATCTGACCAGCCGACAC
 CAAGAAGCAGAGATGGCCAGAAATGCAGTTCGCCTTCACTATGGACTACC
 AGTTGTGGTTAAGCTCTTACACCCACCATCCCACCTGGCCTCTGATAAAGg
 taaattgtcaaagtagaatttacctttgttgcaagaattgaaaatgaagca
 tctctagctgttggatggctgtctaaagcatagtgatcaataagtaggaat
 tgtatccttagtlaagtaggaagtatggctgcgataggggtaagattctg
 aaatgtttgtgtagtcagaactacttttagttgataccaatagatttagt
 gtggtaggaaattttagggtaagaaaatgattttgttgagttgtatgccag 9900

FIG. 3D

```

ttcttctctctctgtttttcagGCTACTGTTGGATTGATTTCGAAATCTTGCC 9950
CTTTGTCCTCCGCAAATCATGCACCTTTGCGTGAGCAGGGTGGCCATTCCACG 10000
ACTAGTTCAGTTGCTTGTTCGTGCACATCAGGATACCCAGCGCCGTACGT
CCATGGGTGGGACACAGCAGCAATTTGTGgttaggttaaatctcttacagtga
tacctggctatctaaaaggaatgcataaaatccaaaggatcctgaacttct
ttctttgggtcattgggtccccccatccgtcttctcctgaagagcfaatgaca
aagtaataaataaataaattacacatttctatggctgcagagaaaaataag
gcatagtgtggccccagtgabatcttcttggacacgctcttcacatggtc
agtcttacaaaggtttgggttaggtgtttcataaagtyttctcatttaatt
tacacaaaaggccacttcttaggaagaggttagagtcataaatttgagatc
aaatctgtgttaatttcagagcctcttacccttgcctcatcatgcattttg
actataaataatttagcagtcctgtttattatctttctgtgagttaaact 10500
tttttcatggacctaaagaatattcagaaaataagtagtagcatttctgtac
tcttaaccacaaaaatctcaacctgaagctttgatataaaagtttgtgtct
taaaagtagcttcattaaaagtatagtcataatgacatttctgatttctca
gactttaagaacctattaggttagtttagaaaaaaaagatggagcctacc
agaacagatgtaggaatctcattttgctggttgctttgtgtatgtactc
atattggggctttggctttcttcaatttactgttgggtattggccctc
tccatgaggtgacttaatagaacgcttgagggcaccttttattttaaactc
ctttctaggaagaagagagttttgtgtccttgaagaatcaagttatt
tataaaagctgctaaatgttagcagaataataaccctttttaaactcaaa
tcagaaaacaggagaaaacagatggtaacttacatattgcaaaagctatctt 11000
ccttctatacatgaggctgtcagctgaatagtccttggaaagagtgaggagt
gaatttttctgctggcaactcgggttagtttttagcagttgggtgctaaaact
tggcaaaagttttcaccaaaatacatggaagatatacaaaaaatagagggggc
atgtaaaaagaaaaacgcttgacatagctcagagcattacttctcatctctc
ctttttatataccttttaccocagaatgattgggtgcccttactgtaggaaa
gttgtctttgggattcagcgtctgtatggaagctctgtttgactgtgtatg
ggggaggggtgctgctttgaattagtgctgccaggaggcctcttttcagt
gacattcaagtttaattggaatccttcttctcctgaactaattgcaagtt
acggggaaactcgggtatataatgtaataaattacagtcataataattgtt
cctcaaacctttacagaggagaatgccctgtttgttaaccatgtttctttt 11500
ggcagGAGGGGGTCCGCATGGAAGAAATAGTTGAAGGTTGTACCGGAGCC
CTTCACATCCTAGCTCGGGATGTTTCAACAACCGAATTGTTATCAGAGGACT
AAATACCAFTCCATTGTTTGTGCAGgtatgttttaagtgaaagtggtctag
gttttatgtccataaaaatttccagattgtaatgactaataaacatttcaga
aaattagggaccataaataggggttaccacatttaattttatgaaaattcc
ctacattttttgggtcagtaagagaaacattgagacttgagaagagggagg
agatttcacatttctcttttatgggtgcttagaggggagagctgacctgg
gctgccagagycagggcatagaccccccaaccaattctgggttttccaaat
cttagatcagttagagctgctctgaagaaagggtttatagctaaaaaat
attatgaaatccagtgctccagagcattaaacaccccagaacataaaaat 12000
tcagagaatattttactacagtggtgaatgcctcttgcactctgaattg
ggaatgthtgcaccacagtggggggcttgccatgttttagcttttagattt
aattaggttttgtttgtgttttctccttagCTGCTTTATTCTCCATTGA
AAACATCCAAAGAGTAGCTGCAGGGGTCTCTGTGAACCTTGCTCAGGACA
AGGAAGCTGCAGAAGCTATTGAAGCTGAGGGAGCCACAGCTCCTCTGACA
GAGTTACTTCACTCTAGGAATGAAGGTGTGGgttaagtataaaaggaaccaa
agcctttagcagatgtgtacattgaagtctcagtttttctcaagggcct
ttttctcctgtctcttagCGACATATGCAGCTGCTGTTTTGTTCCGAAT
GTCTGAGGACAAGCCACAAGATTACAAGAAACGGCTTTCAGTTGAGCTGA
CCAGCTCTCTTCAGAACAGAGCCAATGGCTTGAATGAGgttagggaaa 12500

```

FIG. 3E

```

tgtgagoagttatattatctggtagtttcoctagagoaggtatggcagcttg 12550
ttcttttcoctctcaaaaacacttagtacacattcatttgcattgatgtttcc
ctggcttgagttatctctctttatgctgtctagcaactgctctgaggaag
aactataatacaagctttaaagagctgttcagaatcattacaaaataagt
tgtgttattttaaattataattcataagggagaaagatgaaaaatgttac
cagattaaagaagatttttcaaaaggatgtaaggaaagagggcagtgtaa
acactgttaagaggacagtttatcagttatcttactaaactttaataaa
acttttctatttgaatttctgctatgaatttttcttcagcatttgtcoctc
agtacaggtgggtccttgaaaacattgtttctaataaaaactagaacatcct
gatattttatccattctatagagatcathgagggtaacacagacatacagt 13000
ggattatgtttgttgagtgaaatggaaagagagattgttaggtttacaacg
atgcagctcttgagaccggagtttaagatcagcctgggcaacatagtgaa
accccatcttttagctgggcatggagatggatgctctatagtcctagctact
ggggagacgggggaggaggattgcttgaaaccaggagttaacagactgc
actcagtgacagagccagactccaacacaaaaaaaaaaaaaaaaaaaaaag
caaattaccagtgagtagtgtgttacttgggtttttaataggcatcttat
taacatggttccaacttgagcccttaactttctccacctaccccttccac
aaacctgttttcoactgtcttctctgtcttagttaatgtcagctttgtctg
tccagctgctcaggctaaaacttttctttcatataacacatcctatcagc
agctcctgtttgtgggtaggcattttgccttttttttttttttttttttt 13500
aaaactgctatctctagcatgtagaacagtgcoctggcagcacataatag
gtgcttaataataatattgttgaaagaacaagtcagtgagttttttaat
gtgaggtgcaaaagagaaaaaaaaaagtatctttgaggtgtggagttttga
agaacttccattttctaaagcatttgtgtaatgttggagttacttgttcoct
tttgaatctgaaagtatgctttaaaaaaaaattagtgtacttttgagaat
tttcaattttgctttctattcttcocttgcctttgtgcatgtttatctagACT
GCTGATCTTGGACTTGATATTGGTGCCCAGGGAGAACCCCTTGATATCG
CCAGGATGgtatgtgtctcatatttctogattaactccagatcaagctaa
agtctcaaaaacttttatcagaagagccggtttgcctcatctgggaaaaccag
tgttggcagaaaaagtagtggctcaattaaaagcagttcttaaaattccag 14000
tcagcaacagttatctttaaaggagcagggaaatccagagccacacaatg
agtgcagtaggattacaccaccaacaatacatgctactgctaggcctc
tgcagtgocaggatgttacaatttacctggctttttatctctttttggcc
agaggactcataatacctttgtctacaagctacccaaggaagataggaaa
actcctgtttctaggctcagatctcgggtgggtttttacatagttgcatt
atcatcagggttttcttgaaaagctaatttaaatctgggtaatgaacatg
gaggatggcatagaccactaacaattataactgtcttacattfataaccg
catctgcttctacctaattatgaaaccactaaagcgcagattcttactgt
gagaaataacatgtcaaccctaagataaaaatagttyaggtttcatggaa
atagtgcttttcttagtacttttgggggtgtcacttggcctttttgtca 14500
agatagattacacctgocagacctcattatgtcttaactcctccttccca
tgaacttctcactgcctagggtgggtcacacagtagattcctgcttcttctoc
tcgggaaccccaagtctcttgacaggggtaaatgcagagtggtcaggggt
agactaatgatgtgactaggccctgctgggtgtgctctgatggaaata
gatgttattttgtgtagtctcatgggtggcctggcactgagtaattacttg
gctaaagaaaagctggaggttgaagaggtagaaagcgttgtttctgaca
agtttgcctgctgaactttggatgccttaacctcagtgtaacgtctatgt
ctgcttctctctctctcttttgccttcttcttgcoctattttgttgaca
cctgactctctctagATCCTAGCTATCGTCTTTTCTACTCTGGTGGATAT
GGCCAGGATGCCTTGGGTATGGACCCATGATGGAACATGAGATGGGTGG 15000
CCACCACCCCTGGTGTGACTATCCAGTTGATGGGCTGCCAGATCTGGGGC
ATGCCAGGACCTCATGGATGGGCTGCCCTCCAGGTGACAGCAATCAGCTG
GCTGGTTTTGATACTGACCTGTAA 15100
15124

```

FIG. 3F

Uterine Tumor ID	CTNNB1 Mutation	Esophageal Tumor ID	CTNNB1 Mutation	Liver Tumor ID	CTNNB1 Mutation
TCGA-AP-A0LV-01	D32G	TCGA-R6-A6XQ-01	S33A	TCGA-DD-AAAC-01	D32A,S33Y
TCGA-BK-A0CB-01	D32G	TCGA-R6-A8WG-01	S37F	TCGA-EP-A2KC-01	D32G
TCGA-AX-A05U-01	D32N	TCGA-LN-A7HX-01	R90L	TCGA-G3-A5SL-01	D32G
TCGA-AS-A0GV-01	D32N	TCGA-L5-A4OJ-01	V136A	TCGA-DD-A73D-01	D32G
TCGA-8G-A0VX-01	D32N	TCGA-L5-A8NM-01	X561_splice	TCGA-ED-A7PZ-01	D32G
TCGA-8S-A0T9-01	D32N	TCGA-L5-A8NR-01	Q68* (nonsense/truncating)	TCGA-G3-AAV1-01	D32G
TCGA-A5-A0GX-01	D32Y	TCGA-R6-A8W5-01	E571* (nonsense/truncating)	TCGA-DD-AAACB-01	D32G
TCGA-85-A0K6-01	D32Y	TCGA-VR-AA4G-01	S681F	TCGA-DD-AAAW1-01	D32G
TCGA-8G-A0W2-01	D32Y	TCGA-V5-A7RB-01	K335T	TCGA-UB-A7MD-01	D32N
TCGA-D1-A17S-01	D32Y			TCGA-G3-AAV5-01	D32N
TCGA-AX-A05W-01	G34E			TCGA-DD-AAVY-01	D32N
TCGA-A5-A0VQ-01	G34E			TCGA-DD-A73E-01	D32V
TCGA-A5-A0GN-01	G34R			TCGA-MI-A75H-01	D32V
TCGA-AP-A0LL-01	G34R			TCGA-RC-A6M4-01	D32V
TCGA-8G-A0MU-01	G34R			TCGA-CC-A7IK-01	D32V
TCGA-85-A11F-01	G34R			TCGA-CC-A7IL-01	D32V
TCGA-D1-A102-01	G34R			TCGA-DD-A4NF-01	D32Y
TCGA-D1-A17N-01	G34R			TCGA-G3-AAV3-01	D32Y
TCGA-8S-A0WQ-01	G34V			TCGA-DD-AAW2-01	E54D,T41A
TCGA-D1-A17M-01	G34V,D32N			TCGA-EP-A3RK-01	G34E
TCGA-AX-A0J0-01	M553V,S37F			TCGA-ZS-A9CG-01	G34R
TCGA-D1-A16R-01	Q623E,I355			TCGA-DD-AAAC8-01	G34R
TCGA-85-A0JY-01	R453Q,D32N			TCGA-DD-A1I9-01	G34V
TCGA-AX-A062-01	S33C			TCGA-G3-A3CJ-01	G34V
TCGA-8G-A0MO-01	S33C			TCGA-CC-A9FW-01	G34V
TCGA-A5-A0R9-01	S33C			TCGA-DD-A1E1-01	H36P
TCGA-8S-A0UT-01	S33C			TCGA-DD-A4NI-01	H36P
TCGA-D1-A0ZN-01	S33C			TCGA-DD-AAACD-01	H36P
TCGA-AP-A05N-01	S33F			TCGA-G3-A3CK-01	H36P,S33P
TCGA-AX-A05T-01	S33F			TCGA-ZP-A9D4-01	I355
TCGA-A5-A0GU-01	S33F			TCGA-DD-AAACX-01	

FIG. 4A

TCGA-A5-A0GW-01 S33F
 TCGA-D1-A0ZU-01 S33F
 TCGA-D1-A17C-01 S33F
 TCGA-AP-A0LN-01 S33Y
 TCGA-B5-A0K7-01 S33Y
 TCGA-85-A0JT-01 S33Y
 TCGA-D1-A165-01 S33Y
 TCGA-AP-A0LG-01 S37A
 TCGA-85-A11V-01 S37A
 TCGA-8S-A0V7-01 S37A
 TCGA-AP-A0LJ-01 S37C
 TCGA-85-A0K0-01 S37C
 TCGA-8G-A0LW-01 S37C
 TCGA-AX-A0IS-01 S37C
 TCGA-D1-A15Z-01 S37C
 TCGA-D1-A17T-01 S37C
 TCGA-8G-A0M3-01 S37C,S646F
 TCGA-A5-A0GM-01 S37F
 TCGA-8G-A0MG-01 S37F
 TCGA-8G-A0VT-01 S37F
 TCGA-D1-A0ZQ-01 S37F
 TCGA-D1-A16B-01 S37F
 TCGA-D1-A16Q-01 S37F
 TCGA-D1-A17R-01 S37F
 TCGA-8G-A0MI-01 S37P
 TCGA-AP-A0LE-01 S37P
 TCGA-85-A12L-01 S45C
 TCGA-85-A0TG-01 S45F
 TCGA-85-A11Z-01 T41A
 TCGA-A5-A0GI-01 T41I
 TCGA-8S-A0UJ-01 T41I
 TCGA-85-A11U-01 T41I



TCGA-DD-AAVP-01 I355
 TCGA-EP-A12J-01 S33A
 TCGA-FV-A4ZQ-01 S33C
 TCGA-ED-A7XP-01 S33C
 TCGA-G3-AAV4-01 S33C
 TCGA-DD-AAE3-01 S33C
 TCGA-DD-AAVX-01 S33C
 TCGA-XR-A8TF-01 S33F
 TCGA-DD-AACA-01 S33F
 TCGA-DD-A116-01 S33P
 TCGA-DD-A39V-01 S33P
 TCGA-G3-A6UC-01 S33P
 TCGA-DD-AADE-01 S33P,S45Y
 TCGA-CC-A5UD-01 S33Y
 TCGA-DD-AADD-01 S33Y
 TCGA-KR-A7K0-01 S37A
 TCGA-DD-AAEK-01 S37A
 TCGA-UB-A7MC-01 S37C
 TCGA-DD-AADG-01 S37C
 TCGA-BW-A5NQ-01 S37F
 TCGA-5C-A9VG-01 S37F
 TCGA-DD-AAD0-01 S37Y
 TCGA-4R-AA8I-01 S45F
 TCGA-LG-A9QD-01 S45F
 TCGA-ZP-A9CV-01 S45F
 TCGA-3K-AAZ8-01 S45F
 TCGA-BC-A10U-01 S45F,S45Ffs*5
 TCGA-O8-A75V-01 S45P
 TCGA-RG-A7D4-01 S45P
 TCGA-NI-A8LF-01 S45P
 TCGA-G3-AAV2-01 S45P
 TCGA-G3-AAV6-01 S45P

FIG. 4B

TCGA-2Y-A9H1-01 S45P
 TCGA-WX-AA47-01 S45P
 TCGA-DD-AAEE-01 S45P
 TCGA-DD-AAEH-01 S45P
 TCGA-DD-AAVQ-01 S45P
 TCGA-DD-AAW3-01 S45P
 TCGA-DD-A4NK-01 S45Y
 TCGA-5R-AA1C-01 S45Y
 TCGA-DD-A11D-01 T41A
 TCGA-2Y-A9HB-01 T41A
 TCGA-DD-AACJ-01 T41A
 TCGA-DD-AADU-01 T41A
 TCGA-DD-AAE9-01 T41A
 TCGA-EP-A26S-01 T41I
 TCGA-2Y-A9HA-01 T41I
 TCGA-CC-A74H-01 T42_K49del
 TCGA-DD-A1EA-01 L31_L35del
 TCGA-DD-A1ED-01 V136A
 TCGA-CC-5262-01 W383C
 TCGA-G3-A5S1-01 Y333F
 TCGA-DD-A39Y-01 K181Rfs*28
 TCGA-DD-A1EJ-01 K335I
 TCGA-DD-A3A4-01 K335I
 TCGA-DD-A4NL-01 K335I
 TCGA-MI-A75C-01 K335I
 TCGA-DD-AACK-01 K335I
 TCGA-K7-A6G5-01 K335T
 TCGA-DD-A39W-01 L139F
 TCGA-G3-A25Z-01 L405F
 TCGA-DD-A1EE-01 L405F,K335I
 TCGA-DD-A73A-01 N387I
 TCGA-EP-A3JL-01 N387K



TCGA-8G-A187-01 T41I
 TCGA-AP-A059-01 V199I
 TCGA-B5-A0V8-01 K170M
 TCGA-B5-A11E-01 K354T
 TCGA-AP-A054-01 M688T
 TCGA-AP-A0LM-01 R535Q
 TCGA-AP-A056-01 R587Q,D712N
 TCGA-AX-A0J1-01 R710H
 TCGA-D1-A103-01 A215T

FIG. 4C

TCGA-FV-A2QQ-01 N387K
TCGA-DD-AADM-01 N387K



FIG. 4D

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/058555

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/395 A61K31/337 C07K16/18 C12Q1/6886 A61P35/00
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C12Q C07K A61K A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Bendell et al.: "http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.111", February 2016 (2016-02), XP002777675, Retrieved from the Internet: URL:http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.111 [retrieved on 2018-01-26] the whole document -/--	1-34

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search 26 January 2018	Date of mailing of the international search report 07/02/2018
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Bumb, Peter
--	--

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/058555

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& BENDELL ET AL: "Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+ relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).", JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. Suppl.4, February 2016 (2016-02), pages 111-111, -----	
A	EP 2 963 114 A1 (DAIICHI SANKYO CO LTD [JP]) 6 January 2016 (2016-01-06) claim 1 paragraphs [0055], [0011] -----	1-34
T	FILLMORE REBECCA A ET AL: "Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth.", INTERNATIONAL JOURNAL OF CANCER 01 AUG 2009, vol. 125, no. 3, 1 August 2009 (2009-08-01), pages 556-564, XP002777676, ISSN: 1097-0215 the whole document -----	
T	KATOH MASUKO ET AL: "Molecular genetics and targeted therapy of WNT-related human diseases", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 40, no. 3, September 2017 (2017-09), pages 587-606, XP002777677, the whole document -----	
T	CHO SUN WOOK ET AL: "Dickkopf-1 inhibits thyroid cancer cell survival and migration through regulation of beta-catenin/E-cadherin signaling", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 366, no. 1, February 2013 (2013-02), pages 90-98, XP002777678, ISSN: 0303-7207 the whole document -----	
A	WO 2010/117980 A1 (LILLY CO ELI [US]; CHEDID MARCIO [US]; DARLING RYAN JAMES [US]; GALVIN) 14 October 2010 (2010-10-14) sequences 12,14 example 5 -----	1-34
A	WO 2007/084344 A2 (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; SHULOK JANINE [US]; CONG) 26 July 2007 (2007-07-26) example 17 -----	1-34
	----- -/--	

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/058555

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2008/097510 A1 (MERCK & CO INC [US]; AN ZHIQIANG [US]; CHEN FANG [US]; FISHER JOHN E []) 14 August 2008 (2008-08-14) page 40	1-34
A	----- ILSON D H ET AL: "Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY MAY 2007, vol. 18, no. 5, May 2007 (2007-05), pages 898-902, XP002777679, ISSN: 0923-7534 the whole document	1-34
T	----- WANG YIHUA ET AL: "FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma.", INTERNATIONAL JOURNAL OF CANCER 01 AUG 2008, vol. 123, no. 3, 1 August 2008 (2008-08-01), pages 561-568, XP002777680, ISSN: 1097-0215	
T	----- VEERAMACHANENI NIRMAL K ET AL: "Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells.", THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY JAN 2004, vol. 127, no. 1, January 2004 (2004-01), pages 92-98, XP002777681, ISSN: 0022-5223	
A	----- TAI DAVID ET AL: "Targeting the WNT Signaling Pathway in Cancer Therapeutics.", THE ONCOLOGIST OCT 2015, vol. 20, no. 10, October 2015 (2015-10), pages 1189-1198, XP002777682, ISSN: 1549-490X	1-34
X,P	----- Strickler et al.: "Biomarker Studies in a Phase I Trial of DKN-01 in Advanced Esophageal Cancer", ASCO 2017 February 2016 (2016-02), XP002777683, Retrieved from the Internet: URL:https://www.leaptx.com/file.cfm/17/docs/P102 ASCO GI 2017 01-06-17 final.pdf [retrieved on 2018-01-26] the whole document	1-34
	-/--	

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/058555

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>& Strickler et al.: "Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer.", February 2017 (2017-02), Retrieved from the Internet: URL:http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.161#affiliationsContainer [retrieved on 2018-01-26] & STRICKLER ET AL.: "Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer.", JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. Suppl.5, February 2016 (2016-02), page 161, -----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/058555

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 2963114	A1	06-01-2016	EP 2963114 A1 06-01-2016
			JP WO2014133071 A1 02-02-2017
			US 2016011201 A1 14-01-2016
			WO 2014133071 A1 04-09-2014

WO 2010117980	A1	14-10-2010	AR 075989 A1 11-05-2011
			AU 2010234611 A1 20-10-2011
			CA 2758252 A1 14-10-2010
			CN 102388065 A 21-03-2012
			DK 2417158 T3 16-10-2017
			EA 201171237 A1 30-04-2012
			EP 2417158 A1 15-02-2012
			EP 2930184 A1 14-10-2015
			ES 2644244 T3 28-11-2017
			IL 214845 A 30-06-2016
			JP 5759977 B2 05-08-2015
			JP 2012523417 A 04-10-2012
			KR 20110124364 A 16-11-2011
			KR 20140033523 A 18-03-2014
			KR 20140090273 A 16-07-2014
			LT 2417158 T 10-10-2017
			NZ 595011 A 31-05-2013
			PL 2417158 T3 29-12-2017
			PT 2417158 T 23-10-2017
			SG 175244 A1 29-12-2011
			SI 2417158 T1 30-10-2017
			TW 201100101 A 01-01-2011
			UA 103916 C2 10-12-2013
			US 2010260754 A1 14-10-2010
			WO 2010117980 A1 14-10-2010
			ZA 201107256 B 27-03-2013

WO 2007084344	A2	26-07-2007	AR 060017 A1 21-05-2008
			AU 2007207787 A1 26-07-2007
			BR PI0706524 A2 29-03-2011
			CA 2636579 A1 26-07-2007
			CN 101400406 A 01-04-2009
			CR 10128 A 25-08-2008
			CU 20080133 A7 21-06-2012
			EA 200801679 A1 27-02-2009
			EC SP088618 A 29-08-2008
			EP 1976594 A2 08-10-2008
			GE P20125476 B 25-04-2012
			HK 1121420 A1 25-09-2015
			HN 2008001104 A 08-06-2011
			IL 192631 A 30-06-2015
			JP 5552233 B2 16-07-2014
			JP 2009523421 A 25-06-2009
			JP 2013099334 A 23-05-2013
			KR 20080085908 A 24-09-2008
			MA 30158 B1 02-01-2009
			ME P1308 A 10-02-2010
			MY 153573 A 27-02-2015
			NZ 569555 A 22-12-2011
			PE 08162012 A1 01-08-2012
			PE 12392007 A1 12-02-2008
			SG 169327 A1 30-03-2011
			SM AP200800042 A 30-07-2008

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/058555

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		SV 2008002980 A	21-05-2010
		TN SN08297 A1	29-12-2009
		TW 200804417 A	16-01-2008
		UA 101944 C2	27-05-2013
		US 2012023600 A1	26-01-2012
		US 2014170147 A1	19-06-2014
		US 2014341901 A1	20-11-2014
		WO 2007084344 A2	26-07-2007
		ZA 200805743 B	26-08-2009

WO 2008097510	A1 14-08-2008	AU 2008214344 A1	14-08-2008
		CA 2677356 A1	14-08-2008
		CN 101641373 A	03-02-2010
		EP 2121755 A1	25-11-2009
		JP 2010517570 A	27-05-2010
		JP 2014087366 A	15-05-2014
		US 2008193449 A1	14-08-2008
		US 2012201835 A1	09-08-2012
		WO 2008097510 A1	14-08-2008
